Experience in Combined Therapy for Advanced Renal Cancer.
DOI:
https://doi.org/10.54212/27068048.v8i2.36Keywords:
Advanced Renal Cancer, Sunitinib, Cytoreductive nephrectomyAbstract
INTRODUCTION: In the last decade, radical nephrectomy (RN) has proven to enhance survival of patients with advanced stage renal cancer when combined with systemic therapy to act directly on the proliferation of cancer cells.
MATERIAL AND METHODS: A retrospective study was conducted analyzing 81 patients with advanced renal carcinoma treated in public and private practice from 2008 to 2018. These patients underwent RN and subsequently received anti-angiogenic therapy with sunitinib for advanced disease.
RESULTS: In the 10 year period, 69.2% of the patients undergoing RN were males (n=56). The average age at the time of diagnosis was at 59 (31-80) years.
The most frequent histological type of cancer was clear cell carcinoma in 88.8% of the cases (n=72), and 27.1% (n = 22) had metastatic disease at the time of diagnosis. 96.2% of the patients received Sunitinib as first line treatment, with an average of 6.2 (1-28) cycles.
The mean time to disease progression was 24.4 (2-33) months in patients without previous metastatic disease.
The survival rate of these patients was 46.3 months, and 18.4 months of those who already had metastases. The follow-up time was 30.8 (3-49) months.
CONCLUSION: Combination therapy in patients with advanced renal cancer is a good alternative that can be applied in our environment, with properly patient selection and therapy planning involving a multidisciplinary team.
Downloads
References
Smith MR, et al. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer. Cancer 2011;117 (10) 2077-85. https://doi.org/10.1002/cncr.25762 DOI: https://doi.org/10.1002/cncr.25762
Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 2018:378(15):1408-18. https://doi.org/10.1056/NEJMoa1715546 DOI: https://doi.org/10.1056/NEJMoa1715546
Saad F, et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer(, an análisis of the Spartan trial. Lancet Oncol 2018;19(10):1404-16. https://doi.org/10.1016/S1470-2045(18)30456-X DOI: https://doi.org/10.1016/S1470-2045(18)30456-X
Fizazi K, et al. Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 2019;380(13):1235-46. https://doi.org/10.1056/NEJMoa1815671 DOI: https://doi.org/10.1056/NEJMoa1815671
Hussain M, et al. Enzalutamide in men with nonmetastatic, castration-resitant prostate cancer. N Engl J Med 2018;378(26):2465-74. https://doi.org/10.1056/NEJMoa1800536 DOI: https://doi.org/10.1056/NEJMoa1800536
Penson DF, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer. J Clin Oncol 2016;34(18):2098-106. https://doi.org/10.1200/JCO.2015.64.9285 DOI: https://doi.org/10.1200/JCO.2015.64.9285
Smith MR et al. Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. J Urol 2003;169 2008-2012. https://doi.org/10.1097/01.ju.0000063820.94994.95 DOI: https://doi.org/10.1097/01.ju.0000063820.94994.95
Smith MR, et al. Denosumab a bone metastasis free survival in men with castration-resistant prostate cancer, results of a pase 3 randomized, placebo controlled trial. Lancet 2012; 31 3800-3806. https://doi.org/10.1016/j.yuro.2012.06.017 DOI: https://doi.org/10.1016/j.yuro.2012.06.017
H. Scher et al. Prostate Cancer Working Group. J Clin Oncol 2008 (PCWG).
Heidegger I, et al. Treantment of non-metastasic castration resistant prostate cancer in 2020. J.urolonc.2019; 1 - 8.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2020 Estuardo Polanco G., Alfredo Mansilla, Hugo Castro
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
